Across two research groups comparing patients with craniopharyngioma and healthy controls, no significant differences in baseline salivary oxytocin concentrations were observed (Brandi et al., 2020, Daubenbüchel et al., 2016, Daubenbüchel et al., 2019, Özyurt et al., 2020). This evidence concerns the gene OXT and craniopharyngioma.